1 Steps
Maximum: 1 CME cr.
Sign in to view your progression
Case Study Background
Learning Objectives
Target Audience
Accreditation Information
Disclosures

This educational programme features multiple patient cases focusing on the following themes:

  • Case 1 (Safety Case, First-line therapy: Hepatotoxicity)
  • Case 2 (Safety Case, Second-line immunotherapy: Endocrine toxicity)
  • Case 3 (Drug efficacy, Second-line Immunotherapy)
  • Case 4 (Safety Case, First-line therapy: Skin toxicity)

The program focuses on several treatment scenarios and reviews the latest results of clinical trials assessing checkpoint inhibitors in patients with bladder cancer, in order to help physicians offer a more tailored approach to treatment.

​Upon completion of this educational activity, the participant should be able to:

  • - Describe the current management of platinum-treated metastatic urothelial cancer (mUC)
  • - Describe the current management of platinum-ineligible mUC
  • - Identify key immune-related adverse events
  • - Discuss how patients are being managed using case studies as examples

This program is designed for urologists, medical oncologists, radiation oncologists, residents, and fellows who have an interest in immunotherapy and systemic treatments for bladder cancer around the world who are SIU members or SIU Academy-registered members.

This program is accredited by the European Accreditation Council for Continuing Medical Education (EACCME).

The credits for the users of the module will be 1 European CME credit (ECMEC®) for every hour (60 minutes of actual e-learning excluding introductions etc.) of use, provided that the users have completed a module and have passed the relevant assessment.

Faculty Disclosures and Credentials

CHAIR
Dr. Michiel van der Heijden
Medical Oncologist, Netherlands Cancer Institute
Disclosures: Advisory boards BMS, AstraZeneca, Roche, Merck, Seattle Genetics, Astellas, Janssen

SCIENTIFIC COMMITTEE MEMBERS
Dr. Srikala Sridhar
Medical Oncologist, Princess Margaret Cancer Centre
Associate Professor, Department of Medicine, University of Toronto
Disclosures: Advisory Boards – Merck, Roche, AstraZeneca, Bristol-Myers Squibb, Bayer, Janssen, Astellas


Prof. Dr. med. Axel S. Merseburger
Chairman of the Department of Urology, University of Lübeck
Disclosures: Advisory Boards/Speaker – Merck, Roche, AstraZeneca, Bristol-Myers Squibb, Bayer, Janssen, Astellas, Ferring, Ipsen, Takeda

Applications of Immunotherapy in Bladder Cancer

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies